曲美替尼
医学
达布拉芬尼
MEK抑制剂
黑色素瘤
肺癌
癌症研究
腺癌
威罗菲尼
肺腺癌
V600E型
癌症
MAPK/ERK通路
内科学
激酶
肿瘤科
转移性黑色素瘤
突变
生物
生物化学
基因
细胞生物学
作者
Kento Ichikawa,Shigeru Ohno,Sousuke Kubo,Hideaki Nakajima
出处
期刊:Case Reports
[BMJ]
日期:2024-05-01
卷期号:17 (5): e255958-e255958
标识
DOI:10.1136/bcr-2023-255958
摘要
The combination therapy of v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) and mitogen-activated protein kinase kinase (MEK) inhibitors is approved for treating patients with BRAF V600E-positive tumours, including melanoma and lung cancer. Several case reports indicated autoimmune side effects associated with the use of BRAF and MEK inhibitors. Still, the effects of these drugs on the immune system were not fully elucidated. Here, we report a patient with large-vessel vasculitis diagnosed after initiation of treatment with dabrafenib and trametinib for BRAF V600E-positive metastatic lung adenocarcinoma. She was a never-smoker woman in her early 70s who presented with a chronic cough and was diagnosed with BRAF V600E-positive metastatic lung adenocarcinoma by transbronchial lung biopsy. She was successfully treated with prednisolone and methotrexate while BRAF and MEK inhibitors were continued. We should be careful about autoimmune diseases using BRAF and MEK inhibitors.
科研通智能强力驱动
Strongly Powered by AbleSci AI